Table 2.
Potential novel agents for patients with advanced HCC.
| AGENTS | PHASE STUDY | MECHANISM OF ACTION |
|---|---|---|
| First line | ||
| Sorafenib and erlotinib | III | Multi-kinase inhibitor and anti-angiogenic |
| Second line | ||
| Ramucirumab | II–III | Anti-angiogenic |
| Bevacizumab | II | Anti-angiogenic |
| Cediranib | I–II | Anti-angiogenic |
| Pazopanib | ||
| Lenvatinib | ||
| Lenalidomide | ||
| Axitinib | ||
| Gefitinib | I–II | EGFR inhibitor |
| Lapatinib | ||
| Cetuximab | ||
| Everolimus | III | mTOR inhibitor |
| Sirolimus | I–II | mTOR inhibitor |
| Temsirolimus | ||
| Tivatinib | II | Hepatocyte growth factor/c-MET inhibitor |
| Cabozantinib | ||
| Belinostat | I–II | Histone deacetylase inhibitor |
| STA-9090 | I–II | HSP-90 inhibitor |